BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions

Burney, Claire; Wadhera, Karan; Breslin, Patricia; Pearce, Rachel; Wells, Matthew; Alajangi, Rajesh; Protheroe, Rachel; Marks, David I.; Griffin, James E.; Robinson, Stephen

doi:10.1016/j.bbmt.2020.08.028

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients treated for primary immunodeficiency, EFS was longer, with 78% experiencing EFS 5 years post-HCT [ 21 ]. Long-term survival benefits have also been shown, with 66% of lymphoma patients alive 10 years post-transplant, of whom 45% were progression-free [ 25 ]. Other studies have shown conflicting results, with alemtuzumab-based conditioning conferring no survival benefit in adult acute myeloid leukaemia (AML) patients, although cGvHD incidence was lower.…”

Section: Monoclonal/naked Antibodiesmentioning

confidence: 99%

“…Further studies revealed mixed chimerism in both the myeloid and T cell lineages, albeit to a greater extent in the T cell lineage. Importantly, mixed chimerism was not associated with increased risk of key outcome measures, such as OS, GvHD and relapse [ 25 ]. Donor lymphocyte infusions (DLI) were necessary to achieve full chimerism in most cases [ 25 , 26 ].…”

Section: Monoclonal/naked Antibodiesmentioning

confidence: 99%

“…Importantly, mixed chimerism was not associated with increased risk of key outcome measures, such as OS, GvHD and relapse [ 25 ]. Donor lymphocyte infusions (DLI) were necessary to achieve full chimerism in most cases [ 25 , 26 ]. Indeed, a greater number of DLI have been required in patients whose conditioning regimens contained alemtuzumab, although this could be as a result of disease relapse [ 26 ].…”

Section: Monoclonal/naked Antibodiesmentioning

confidence: 99%

See 2 more Smart Citations

Worked to the bone: antibody-based conditioning as the future of transplant biology

et al. 2022

View full text Add to dashboard Cite

Conditioning of the bone marrow prior to haematopoietic stem cell transplant is essential in eradicating the primary cause of disease, facilitating donor cell engraftment and avoiding transplant rejection via immunosuppression. Standard conditioning regimens, typically comprising chemotherapy and/or radiotherapy, have proven successful in bone marrow clearance but are also associated with severe toxicities and high incidence of treatment-related mortality. Antibody-based conditioning is a developing field which, thus far, has largely shown an improved toxicity profile in experimental models and improved transplant outcomes, compared to traditional conditioning. Most antibody-based conditioning therapies involve monoclonal/naked antibodies, such as alemtuzumab for graft-versus-host disease prophylaxis and rituximab for Epstein–Barr virus prophylaxis, which are both in Phase II trials for inclusion in conditioning regimens. Nevertheless, alternative immune-based therapies, including antibody–drug conjugates, radio-labelled antibodies and CAR-T cells, are showing promise in a conditioning setting. Here, we analyse the current status of antibody-based drugs in pre-transplant conditioning regimens and assess their potential in the future of transplant biology.

show abstract

Section: Monoclonal/naked Antibodiesmentioning

confidence: 99%

Section: Monoclonal/naked Antibodiesmentioning

confidence: 99%

Section: Monoclonal/naked Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Worked to the bone: antibody-based conditioning as the future of transplant biology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Mixed chimerism following alloSCT is a common entity following HSCT. Most publications have defined mixed chimerism as the presence of between 5 and 95% donor cells post alloSCT [56][57][58]. The frequency of mixed chimerism in alloSCT populations is dependent on certain variables.…”

Section: Mixed Chimerism With Cytopenias (Mcc)mentioning

confidence: 99%

Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review

Prabahran

Koldej

Chee

et al. 2022

Bone Marrow Transplant

View full text Add to dashboard Cite

The development of non-relapse cytopenias (NRC) is a relatively common occurrence post allogeneic stem cell transplant (alloSCT). Whilst there have been attempts to classify post alloSCT cytopenias by transplantation groups, ambiguity of definitions in prior publications compounded by a lack of availability of high-quality evidence, provide challenges to clinicians attempting to manage these complex patients. In this review we describe 3 cases of NRC, (1) Graft Failure with graft rejection representing cytopenias with minimal donor chimerism (2) Poor Graft Function representing cytopenias with complete donor chimerism and (3) Cytopenias with mixed donor chimerism. This case-based review will evaluate the currently available evidence regarding the pathophysiology of each entity as well as the evidence for current therapies with the aim of providing guidance to clinicians managing these complex patients.

show abstract

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Fallahi

Zerangian

Deravi

et al. 2024

CCTR

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on under-standing its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system lead-ing to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underly-ing mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding.

show abstract

BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions

Cited by 3 publications

References 29 publications

Worked to the bone: antibody-based conditioning as the future of transplant biology

Worked to the bone: antibody-based conditioning as the future of transplant biology

Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Contact Info

Product

Resources

About